All News - ALZFORUM
5 days ago · TYPE OF NEWS. Research News (4502) Conference Coverage (1405) Community News (278) Interviews (33) Book Reviews (7) DISEASE. Alzheimer's Disease (3333) Amyotrophic Lateral Sclerosis (541) Parkinson's Disease (477) Frontotemporal Dementia (434) Triplet Repeat Diseases (153) Dementia with Lewy Bodies (116) Progressive Supranuclear Palsy (95 ...
ALZFORUM | NETWORKING FOR A CURE
3 days ago · Most scientists agree that for amyloidosis to ignite, both ApoE and microglia need to be present. A new study presents a mechanistic link between the two. Scientists report that ApoE and Aβ both aggregate within microglial lysosomes, and that these intracellular liaisons ultimately seed amyloid plaques.
2023—A Bumper Year for the Treatment and Science of Alzheimer's
Dec 26, 2023 · Lecanemab (bottom panel) reduced plaque load over the same period. [Courtesy of Eisai.] Alzforum's raison d'etre, it could be said, is to facilitate the search for treatments for Alzheimer's and related diseases. The year 2023 was a good year for this, as the U.S. FDA approved several drugs, compared to none in 2022.
A New Era of Alzheimer’s Treatment - ALZFORUM
Print. 22 Jun 2021. The Food and Drug Administration’s decision to greenlight aducanumab (trade name Aduhelm) for Alzheimer’s disease has touched off an explosion of criticism and debate (see Part 1 of this series). Some researchers, however, consider the approval an overall positive development that the neurodegeneration field can build on ...
Aducanumab Approved to Treat Alzheimer’s Disease
07 Jun 2021. In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid antibody aducanumab, now called Aduhelm, removes amyloid plaque from the brain, but its ability to slow cognitive decline has ...
How Will Alzheimer’s Trials, Treatment Change in 2023 and Beyond?
Tools. 07 Oct 2022. When Eisai and Biogen announced positive top-line results for their anti-amyloid antibody lecanemab, the trial became the first successful, completed Phase 3 Alzheimer's drug study in the Western world in more than 20 years. If lecanemab earns traditional approval from the U.S. Food and Drug Administration based on these ...
Do Two APOE4 Alleles Always Mean Alzheimer's? - ALZFORUM
Tools. 10 May 2024. For 30 years, APOE4 has ranked as the strongest genetic risk factor for Alzheimer’s disease, with two copies boosting the odds up to 15-fold. Now, scientists make the case that people with two APOE4 alleles are not merely at risk, but are destined to develop AD. As reported in Nature Medicine on May 6, researchers led by ...
Revised Again: Alzheimer's Diagnostic Criteria Get Another …
Sep 16, 2022 · Tools. 17 Aug 2023. Diagnostic criteria for Alzheimer’s disease were revised only five years ago, but the field has learned a lot since then. At the Alzheimer’s Association International Conference, held last month in Amsterdam, Clifford Jack of the Mayo Clinic in Rochester, Minnesota, proposed updates to the current “ATN” system.
Alzheimer’s Gene BIN1 Promotes Synaptic Transmission
Mar 18, 2020 · BIN1, one of the strongest genetic risk factors for late-onset Alzheimer’s disease, encodes a protein that dabbles in many cellular functions, taking a hand in Aβ production, tau propagation, and microglial function. Now, in the March 10 Cell Reports, researchers led by Gopal Thinakaran at the USF Morsani College of Medicine in Tampa ...
Alzheimer’s Gene MS4A4A Governs the State of Microglia
Mar 3, 2023 · It lowered expression of MS4A4A itself. Some of these data were previously presented at the 2021 Alzheimer’s Association International Conference (Aug 2021 conference news). More Greens, Please. In people with the more common GG allele at the rs1582763 locus, few microglia assume the anti-inflammatory interferon profile (green).